cevimeline hydrochloride
Phase 3Completed 0 watching 0 views this week๐ Rising
77
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Head and Neck Cancer
Conditions
Head and Neck Cancer, Oral Complications, Radiation Toxicity
Trial Timeline
Jun 1, 2001 โ Mar 1, 2003
NCT ID
NCT00017511About cevimeline hydrochloride
cevimeline hydrochloride is a phase 3 stage product being developed by Daiichi Sankyo for Head and Neck Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00017511. Target conditions include Head and Neck Cancer, Oral Complications, Radiation Toxicity.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00017511 | Phase 3 | Completed |
Competing Products
20 competing products in Head and Neck Cancer